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Abstract
Dengue is a mosquito-borne viral disease of humans that is a major public health concern in tropical and sub-
tropical regions of the world. The increasing mortality and morbidity rates caused by infection in recent years
are attributable partly to a lack of availability of eﬀective antiviral therapies and vaccines. In a concerted
attempt to arrest this global expansion, several dengue vaccine candidates have progressed from pre-clinical
testing into clinical trials. However, the advancement of vaccine development has manifest challenges to be
overcome. A principal tenet underpinning dengue vaccine design is balanced immunity to all ﬁve recognised
virus serotypes, but diﬃculties in achieving optimal attenuation of each virus and interference between
individual attenuated viruses are signiﬁcant hurdles to successful implementation. Currently, the most
advanced vaccine candidate, the recombinant, live-attenuated ChimeriVax-DEN1-4 preparation developed
by Sanoﬁ Pasteur, is likely to achieve licensure at the completion of phase III trials and undergo population
safety surveillance. Subunit and DNA vaccines are also in various stages of clinical evaluation. The intrinsic
rationale is to produce a safe, eﬃcacious and cost-eﬀective vaccine. While this remains an achievable
goal, progress is limited by an incomplete understanding of dengue viral pathogenesis, together with a
lack of suitable animal models for fundamental pre-clinical development. This editorial highlights current
approaches and future directions for vaccine strategies to combat the global expansion of this infectious
disease.
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Introduction
Dengue is a vector-borne disease of humans that
is transmitted by mosquitoes of the species Aedes
aegypti and, less frequently, Aedes albopictus [1].
The causative agent of infection is Dengue Virus
(DENV), which belongs to genus Flavivirus of the
family Flaviviridae [2]. Other members of this family
are responsible for a number of notable infectious
diseases in humans, such as yellow fever, West
Nile encephalitis, Japanese encephalitis and hepatitis
C virus infection. DENV is an enveloped, single-
strand, positive sense RNA virus. The 10.7 kilobase
genome encodes a precursor polypeptide in which
post-translational cleavage by a host cell and virus-
encoded protease results in formation of three
structural proteins – capsid (C), membrane (M), and
envelop (E), and seven non-structural proteins –
NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5 [2,3].
These structural and non-structural proteins play
several functions in the life cycle and pathogenesis
of DENV. They are therefore potential targets
for host immune responses and hence also for
vaccine design. In particular, E protein, as its name
suggests, is the principal surface protein of the
virion, and is involved in host cell attachment,
typically to keratinocytes, the predominant cell type
in human skin. E protein presents a major target
for humoral immunity and mutation aﬀects DENV
virulence [3]. Of the non-structural proteins, NS1 is
a highly conserved glycoprotein that, while detailed
biological functions are yet to be ascribed, appears
essential to pathogenesis. It is present in elevated
concentrations in sera of dengue-infected patients
during the early clinical phase of infection [4].
There are ﬁve antigenically distinct serotypes of
DENV, the last one of which was discovered only
very recently [5]. Named DENV-1 to -5, they are
distinguished by a plaque reduction neutralization
test. Separate serotypes frequently co-circulate in
the same locality. Infection will engender lifelong
immunity to the exposed serotype but provide only
transient protection against others [3,6]. However,
in cases of re-infection by a heterologous dengue
serotype with the presence noted of cross-reactive
antibodies [7] and/or cross-reactive T cells [8,9], the
potential risk of antibody-dependent enhancement
of disease is increased. Indeed, the greatest risk
factor for dengue haemorrhagic fever is secondary
infection.
Over several decades the rising public health
burden of dengue has provoked widespread
international concern. The causes for an increase
in cases are multifactorial but include urbanization,
climate change, globalization and human population
growth, which have facilitated both clustering
and dispersal of hosts, vectors and viruses [10].
At present, more than 2.5 billion people are
at risk of infection in over 125 countries of
2the tropics and subtropics [1]. Recent estimates
suggest that there are 390 million cases of
dengue annually, of which 96 million present with
clinicalor subclinical severity [11]. Of these, around
500,000 require hospitalization with life-threatening
complications, resulting in up to 20,000 deaths
[2,12]. Dengue infection presents clinically as a
spectrum ranging from mild, self-limiting febrile
illness to severe forms like haemorrhagic fever with
warning signs (abdominal pain, persistent vomiting,
ﬂuid accumulation, mucosal bleeding, lethargy,
increased haematocrit with decreasing platelets),
and life-threatening shock syndrome (with profound
plasma leakage, severe bleeding, or organ failure)
[13].
There is no speciﬁc therapy for dengue, only
supportive treatments for symptoms, including oral
rehydration, administration of intravenous ﬂuids
and/or blood transfusion. Hence, there is an
imperative need for intervention approaches based
on either vector control or human vaccination
if the current upward epidemiological trend is
to be reversed [14,15]. Although clinical testing
of attenuated vaccine candidates began in the
1980s [16], a licenced vaccine is not yet available.
The challenge to vaccinologists is to achieve pan-
serotype immunity without triggering associated
pathology [7]. An overriding principle driving vaccine
design is balanced immunity to all ﬁve now identiﬁed
viruses. An intensive, cross-disciplinary research
eﬀort aims at producing an eﬀective multivalent
vaccine for prophylactic immunization [17]. To date,
a variety of approaches has been undertaken to
produce a prototype vaccine.
Live-attenuated tetravalent
dengue vaccine
Live-attenuated vaccines (LAV) aim to mimic natural
infection by inducing humoral and cellular responses
to both structural and non-structural proteins of
the virion using a harmless or less virulent form
of the live virus. The ﬁrst dengue tetravalent
LAV evaluated in clinical trials was initiated by
the University of Hawaii, USA, then developed by
Mahidol University, Bangkok, Thailand, and licensed
to Aventis Pasteur (now Sanoﬁ Pasteur, Lyon, France)
[18]. Attenuation of DENV-1 to -4 viral strains
for this vaccine was achieved by serial passage
through in vitro epithelial cell cultures of primary
dog kidney (PDK) or primary African green monkey
kidney lines [19]. Another classic LAV was developed
by the Walter Reed Army Institute of Research,
Silver Spring, USA, and licensed to GlaxoSmithKline,
Brentford, UK. This candidate has used serially
diluted DENV attained by passaging in PDK cells
and foetal rhesus lung cells [20]. Reports indicated
promising seroconversion rates for each monovalent
vaccine but unsatisfactory antibody responses to
the tetravalent form [21]. Serial passage of virus
in cell culture often produces erratic molecular
changes through spontaneous genetic mutation
and hence the degree of attenuation may vary.
Interference between four individual attenuated
viruses is potentially a signiﬁcant obstacle to
progress [22]. Attenuation has also been attempted
by introducing a speciﬁc genetic mutation into the
virus genome, which has the eﬀect of interfering
with the virion's ability to replicate. Initial diﬃculty
lay in achieving optimal attenuation of each of the
four tested DENV serotypes, all of which are needed
to provide a required minimal level of reactogenicity
and optimum immunogenicity [23,24]. Subsequent
attempts to address this problem used reverse
genetics to attenuate the virus with mutations
in the 3'UTR region in order to generate
genetically stable attenuated strains [25]. In addition
to viral interference, symptoms of dengue-like
fever were observed when the LAV preparation
was administered to Thai and Australian healthy
volunteers [26,27]; this led to the discontinuation of
the Sanoﬁ Pasteur vaccine in phase II clinical trials.
Mahidol University,in collaborationwith the Chemo-
Sero-Therapeutic Research Institute (Kumamoto,
Japan) and the Pune-based Serum Institute of
India, has since resumed further evaluation of this
preparation in pursuit of a second generation LAV
that shows suitable multivalent immunogenicity but
with much reduced side eﬀects [28,29].
Recombinant tetravalent
dengue vaccine
A chimeric vaccine strategy uses genetic engineering
technology to produce a recombinant construct
using the‘backbone’of the related yellow fever
virus fromwhich the pre-membrane (prM) and E
gene products are replaced with the corresponding
proteins from DENV. Hence, the backbone still
contains the capsid, non-structural proteins and 5'-
and 3'-untranslated regions. The principle of this
formulation is to retain the attenuation properties
from the parent viral vaccine while simultaneously
incorporating dengue antigenicity [29]. Various
chimeric vaccines are in diﬀerent phases of
clinical trial. Sanoﬁ Pasteur’s ChimeriVax tetravalent
DENV vaccine (TDV), which contains prM/E genes
derived from each of the ﬁrst four characterized
serotypes of DENV and 17 D yellow fever virus
as backbone, has been tested already in adult
human volunteers in the United States, Philippines
and Mexico [25]. Pre-clinical phase I and II trials
demonstrated mild to moderate adverse eﬀects [30].
It is encouraging to note that seroconversion rates
after completion of a three dose immunization of
ChimeriVax-DEN1-4 vaccine ranged from 77-100%
and were considered satisfactory [31]. Furthermore,
a subsequent study showed that this vaccine was
well-tolerated and elicited neutralizing antibody
responses against all four DENV serotypes in both
ﬂavivirus seropositive and seronegative participants
[32]. A higher immune response to vaccination was
observed in seropositive individuals, suggesting that
pre-existing seropositivity may increase the vaccine-
induced antibody response to immunization[29].If
ongoing phase IIb/III trials are successful, Sanoﬁ
Pasteur will prepare an application for licensure from
federal health authorities in the near future [15,33].
3DNA-based dengue vaccines
An alternative method described to attenuate DENV
is the use of reverse genetics to mutate the 3'-
untranslated region of cDNA clones [34]. The method
was developed by the National Institute of Allergy
and Infectious Diseases, Bethesda, USA, and is based
on deletion of a sequence of 30 nucleotides. A
successful balance between immunogenicity and
attenuation was reported for DENV-1 and -4
when immunized in rhesus monkeys and human
volunteers. However, optimism was tempered by the
observation in macaques of only partial attenuation
of DENV-2 and no attenuation of DENV-3 [35]. A
possible resolution of this limitation is to make
a chimeric vaccine using the backbone of the
DEN4Δ30 candidate to create similar preparations
to target DENV-1, -2 and -3. The DEN4Δ30-based
tetravalent vaccine has shown to be attenuated and
immunogenic in rhesus monkeys, warranting further
phase I/II testing [36]. In spite of excellent results for
DENV-1 and -2, over-attenuation was detected for
DENV-3 (rDV3/4 Δ30), such that its immunogenicity
was insuﬃciently low. In order to enhance this
candidate, an additional 31-nucleotide deletion was
performed, with improved performance [37].
The Centers for Disease Control and Prevention
(Atlanta, USA) and Takeda Pharmaceuticals (Osaka
Japan) have also produced a chimeric vaccine
candidate, DENVax, using the infectious cDNA clone
derived from a DENV-2-PDK-53 strain developed
at Mahidol University as backbone [38]. Intertypic
recombination of DENV prM/E to replace the
corresponding DENV-2 parental gene produced
attenuated chimeric strains, each of which was
transfected into Vero immortalized monkey kidney
cells. Three sequential plaque puriﬁcations of each
virus were performed to reduce genetic variation
and to thereby ensure safety of the master seed
virus. The resultant candidate vaccine was safe and
immunogenic when tested in cynomolgus monkeys
[39]. It has now progressed to phase II clinical trials in
Puerto Rico, Colombia, Singapore and Thailand [29].
Subunit tetravalent dengue
vaccine
A subunit formulation aims to deliver a TDV
through overcoming issues of viral interference by
adjusting the dose for each of the four recombinant
proteins. Furthermore, it avoids the unpredictable
interactions between viruses as experienced for a
LAV. Bacteria (Escherichia coli), yeast (Pichia pastoris),
virus (baculovirus) and plant cells have each been
utilized successfully to express recombinant dengue
E protein [16]. Correct folding is required to preserve
the integrity of its neutralizing epitopes which
requires co-expression of the prM protein that acts
as a chaperone for E by facilitating folding, then
traﬃcking through the secretory pathway[25]. Co-
expression of E and prM can induce the formation
of highly antigenic virus-like particles. Low yield and
improper folding of E protein were overcome by C-
terminally truncated E proteins produced in an insect
cell expression system. Hawaii Biotech (now part of
Merck, Kenilworth, USA) has developed the vaccine
DEN-80Es (full length prM and 80% E derived from
four serotypes) produced in Drosophila S2 cells [40].
Tetravalent DNA vaccine with
adjuvant
The US Naval Medical Research Center (Bethesda,
USA) and Vical Inc. (San Diego, USA) developed
a DNA-based TDV consisting of DENV epitopes
expressed in a plasmid. The fundamental
principle behind this design is that when
injected subcutaneously or into skin or muscle,
antigen-presenting cells phagocytose the plasmid
whereupon the encoded genes are expressed
intracellularly to generate target antigens.
When presented in association with major
histocompatibility complex class II molecules to the
immune system this will stimulate both humoral and
cellular responses. The antibody response to dengue
in humans is directed at a variety of DENV proteins,
including C, prM, E, NS1, NS3, NS4B and NS5.
The majority of anti-dengue neutralizing antibody
epitopes have been mapped to the E protein.
The lipid-based adjuvant Vaxfectin, a tetravalent
formulation, increased immunogenicity in non-
human primates [41], and has recently entered a
phase I clinical trial [37].
Current challenges and future
directions
Recent research eﬀorts have been directed to
produce a highly eﬀective dengue vaccine against
homotypic and heterotypic infection. A priority
is that this should be safe to administer and
economic to produce. However, several obstacles
for the development of dengue vaccines are making
this a very challenging goal. These include an
insuﬃciently deﬁned pathogenesis and a lack of
suitable experimental models [42]. The most widely
used animal model is the laboratory mouse, in
which DENV replicates poorly. Vero and LLC-MK2
monkey kidney cell lines are standardly used for
performing the neutralization test. However, as the
widely accepted hypothesis of dengue pathogenesis
involves binding of a virion to Fcγ receptor-bearing
phagocytic cells, more appropriate cell lines for
experimental studies include U937, THP-1, K562 and
BHK. The eﬃcacy of vaccines currently on a path to
licensing should be assessed in diﬀerent settings and
clinical conditions [15]. Using immunocompromised
animal models would be an eﬀective method to
identify vaccine outcomes in immunosuppressed
hosts. Furthermore, detailed examination of dose
and delivery of each TDV may overcome the potential
hurdles of reducing viral interference and achieving
balanced immunity. Inactivated whole virus is an
alternative option to live vaccines and oﬀers the
perceived advantages over TDV approaches of no
possibility of reversion to virulence and relative
ease of induction of a balanced immune response.
However, a number of challenges remain, such as
4lack of immunity to NS proteins and a requirement to
employ adjuvants to enhance immunogenicity.
Conclusions
Although there are quite a few TDV candidates
undergoing pre-clinical testing or in clinical
trials, an eﬀective DENV vaccine has yet to
become commercially available. Several of the TDV
candidates have not fulﬁlled their early promise
in animal models by eliciting immunity against
each of the four dengue serotypes tested in
human participants. Hence, development of a second
generation of new or reﬁned vaccine candidates is
most likely required to provide protection against
all serotypes, including the recently recognized ﬁfth
serotype.
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